Literature DB >> 22258252

HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes.

Nicole A Doria-Rose1, Mark K Louder, Zhongjia Yang, Sijy O'Dell, Martha Nason, Stephen D Schmidt, Krisha McKee, Michael S Seaman, Robert T Bailer, John R Mascola.   

Abstract

HIV-1 neutralizing monoclonal antibodies (MAbs) define key targets for vaccine development and are being considered for passive prevention of infection. We analyzed the interaction of MAbs to two independent epitopes on the viral envelope glycoprotein. Potently neutralizing MAbs to the CD4 binding site and V1V2 region displayed no in vitro cross-competition and displayed additive, though not synergistic, neutralization activity. Predicted neutralization coverage of a combination of two MAbs reached 97% on a 208-isolate panel.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22258252      PMCID： PMC3302320          DOI： 10.1128/JVI.06745-11

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  39 in total

1.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.

Authors:  T W Baba; V Liska; R Hofmann-Lehmann; J Vlasak; W Xu; S Ayehunie; L A Cavacini; M R Posner; H Katinger; G Stiegler; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; Y Lu; J E Wright; T C Chou; R M Ruprecht
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

2.  Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.

Authors:  M B Zwick; M Wang; P Poignard; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

4.  Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6.

Authors:  F Verrier; A Nádas; M K Gorny; S Zolla-Pazner
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

5.  Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.

Authors:  Ronald S Veazey; Robin J Shattock; Melissa Pope; J Christian Kirijan; Jennifer Jones; Qinxue Hu; Tom Ketas; Preston A Marx; Per Johan Klasse; Dennis R Burton; John P Moore
Journal:  Nat Med       Date:  2003-02-10       Impact factor: 53.440

6.  Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3-directed monoclonal antibodies.

Authors:  B J Potts; K G Field; Y Wu; M Posner; L Cavacini; M White-Scharf
Journal:  Virology       Date:  1993-11       Impact factor: 3.616

7.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.

Authors:  T Muster; F Steindl; M Purtscher; A Trkola; A Klima; G Himmler; F Rüker; H Katinger
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

Review 8.  Immunoprophylaxis to prevent mother-to-child transmission of HIV-1.

Authors:  Jeffrey T Safrit; Ruth Ruprecht; Flavia Ferrantelli; Weidong Xu; Moiz Kitabwalla; Koen Van Rompay; Marta Marthas; Nancy Haigwood; John R Mascola; Katherine Luzuriaga; Samuel Adeniyi Jones; Bonnie J Mathieson; Marie-Louise Newell
Journal:  J Acquir Immune Defic Syndr       Date:  2004-02-01       Impact factor: 3.731

9.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

Authors:  D R Burton; J Pyati; R Koduri; S J Sharp; G B Thornton; P W Parren; L S Sawyer; R M Hendry; N Dunlop; P L Nara
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

10.  Antibody-based protection against HIV infection by vectored immunoprophylaxis.

Authors:  Alejandro B Balazs; Joyce Chen; Christin M Hong; Dinesh S Rao; Lili Yang; David Baltimore
Journal:  Nature       Date:  2011-11-30       Impact factor: 49.962
View more
  54 in total

1.  A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies.

Authors:  Nicole A Doria-Rose; Ivelin Georgiev; Sijy O'Dell; Gwo-Yu Chuang; Ryan P Staupe; Jason S McLellan; Jason Gorman; Marie Pancera; Mattia Bonsignori; Barton F Haynes; Dennis R Burton; Wayne C Koff; Peter D Kwong; John R Mascola
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

2.  Mining the mechanisms of an HIV vaccine.

Authors:  Stanley A Plotkin; Harriet L Robinson; Miles P Davenport
Journal:  Nat Med       Date:  2012-07-06       Impact factor: 53.440

3.  Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues.

Authors:  Anthony P West; Louise Scharf; Joshua Horwitz; Florian Klein; Michel C Nussenzweig; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-10       Impact factor: 11.205

Review 4.  Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Nat Rev Immunol       Date:  2013-09       Impact factor: 53.106

Review 5.  Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity.

Authors:  Laura A VanBlargan; Leslie Goo; Theodore C Pierson
Journal:  Microbiol Mol Biol Rev       Date:  2016-10-26       Impact factor: 11.056

6.  Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.

Authors:  Lindsay Wieczorek; Shelly J Krebs; Vaniambadi Kalyanaraman; Stephen Whitney; Sodsai Tovanabutra; Carlos G Moscoso; Eric Sanders-Buell; Constance Williams; Bonnie Slike; Sebastian Molnar; Vincent Dussupt; S Munir Alam; Agnes-Laurence Chenine; Tina Tong; Edgar L Hill; Hua-Xin Liao; Michael Hoelscher; Leonard Maboko; Susan Zolla-Pazner; Barton F Haynes; Michael Pensiero; Francine McCutchan; Shawyon Malek-Salehi; R Holland Cheng; Merlin L Robb; Thomas VanCott; Nelson L Michael; Mary A Marovich; Carl R Alving; Gary R Matyas; Mangala Rao; Victoria R Polonis
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

7.  Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.

Authors:  Andrew T McGuire; Jolene A Glenn; Adriana Lippy; Leonidas Stamatatos
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

8.  Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived from Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope.

Authors:  Rebecca T van Dorsten; Bronwen E Lambson; Constantinos Kurt Wibmer; Marc S Weinberg; Penny L Moore; Lynn Morris
Journal:  J Virol       Date:  2020-01-06       Impact factor: 5.103

Review 9.  Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.

Authors:  Laurent Verkoczy; Frederick W Alt; Ming Tian
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

10.  Coverage of primary mother-to-child HIV transmission isolates by second-generation broadly neutralizing antibodies.

Authors:  Kyle J Nakamura; Chiara Cerini; Edwin R Sobrera; Laura Heath; Moses Sinkala; Chipepo Kankasa; Donald M Thea; James I Mullins; Louise Kuhn; Grace M Aldrovandi
Journal:  AIDS       Date:  2013-01-28       Impact factor: 4.177
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.